SCHEMBL2773749

SCHEMBL2773749

O=C(NCC1CCCO1)c1nn(-c2ccc(F)cc2F)c2c1Cc1cc(Br)sc1-2

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 5/20 0.49
▸ CNR1 P21554 1/20 0.46
▸ RAB9A P51151 4/20 0.43
▸ HPGD P15428 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ NAMPT P43490 2/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772703 0.88 CNR2 (0.50) CNR2CNR1RAB9ANPC1
SCHEMBL2772363 0.81 CNR2 (0.52) CNR2CNR1
SCHEMBL2774194 0.79 L3MBTL1 (0.39) CNR2CNR1
SCHEMBL13157524 0.79 CNR2 (0.43) CNR2CNR1
SCHEMBL2775152 0.79 CNR2 (0.43) CNR2CNR1
SCHEMBL29717805 0.76 CNR2 (0.77) CNR2CNR1
SCHEMBL29717816 0.76 CNR2 (0.77) CNR2CNR1
SCHEMBL29718078 0.76 CNR2 (0.77) CNR2CNR1
SCHEMBL2773251 0.76 KDM4E (0.43) CNR2CNR1HPGDCYP1A2CYP2C19
SCHEMBL1431901 0.74 CNR2 (0.63) CNR2CNR1RAB9AHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2230243-A1 Pharmaceutical compounds Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-09-22 — — EP disclosed
EP-2230243-A1 Pharmaceutical compounds Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-09-22 — — EP disclosed
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) 2010-08-26 — — US disclosed
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) 2010-08-26 — — US disclosed
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) 2010-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS CNR2, CNR1, OPRK1 CNR2 1/4885CNR1 2/4885RAB9A 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback